Switch theme
Sign up to access all valuation multiples
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
2010
107
LTM Revenue $0.1M
LTM EBITDA -$79.6M
$113M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fractyl Health has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$79.6M.
In the most recent fiscal year, Fractyl Health achieved revenue of $0.1M and an EBITDA of -$92.9M.
Fractyl Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fractyl Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | -$45K | XXX | $43K | XXX | XXX | XXX |
| Gross Margin | -83% | XXX | 46% | XXX | XXX | XXX |
| EBITDA | -$79.6M | XXX | -$92.9M | XXX | XXX | XXX |
| EBITDA Margin | -146004% | XXX | -99843% | XXX | XXX | XXX |
| EBIT | -$83.6M | XXX | -$93.5M | XXX | XXX | XXX |
| EBIT Margin | -153330% | XXX | -100571% | XXX | XXX | XXX |
| Net Profit | -$72.3M | XXX | -$68.7M | XXX | XXX | XXX |
| Net Margin | -132634% | XXX | -73865% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fractyl Health's stock price is $2.
Fractyl Health has current market cap of $93.2M, and EV of $113M.
See Fractyl Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $113M | $93.2M | XXX | XXX | XXX | XXX | $-1.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fractyl Health has market cap of $93.2M and EV of $113M.
Fractyl Health's trades at 1209.9x EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Fractyl Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fractyl Health has a P/E ratio of -1.3x.
See valuation multiples for Fractyl Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $93.2M | XXX | $93.2M | XXX | XXX | XXX |
| EV (current) | $113M | XXX | $113M | XXX | XXX | XXX |
| EV/Revenue | 2063.6x | XXX | 1209.9x | XXX | XXX | XXX |
| EV/EBITDA | -1.4x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | -2474.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFractyl Health's revenue per employee in the last FY averaged $1K, while opex per employee averaged $0.9M for the same period.
Fractyl Health's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fractyl Health's rule of X is -146004% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fractyl Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -146004% | XXX | -99843% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -146004% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 75775% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 100617% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fractyl Health acquired XXX companies to date.
Last acquisition by Fractyl Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Fractyl Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fractyl Health founded? | Fractyl Health was founded in 2010. |
| Where is Fractyl Health headquartered? | Fractyl Health is headquartered in United States of America. |
| How many employees does Fractyl Health have? | As of today, Fractyl Health has 107 employees. |
| Who is the CEO of Fractyl Health? | Fractyl Health's CEO is Dr. Harith Rajagopalan, M.D.,PhD. |
| Is Fractyl Health publicy listed? | Yes, Fractyl Health is a public company listed on NAS. |
| What is the stock symbol of Fractyl Health? | Fractyl Health trades under GUTS ticker. |
| When did Fractyl Health go public? | Fractyl Health went public in 2024. |
| Who are competitors of Fractyl Health? | Similar companies to Fractyl Health include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Fractyl Health? | Fractyl Health's current market cap is $93.2M |
| What is the current revenue of Fractyl Health? | Fractyl Health's last 12 months revenue is $0.1M. |
| What is the current EV/Revenue multiple of Fractyl Health? | Current revenue multiple of Fractyl Health is 2063.6x. |
| Is Fractyl Health profitable? | Yes, Fractyl Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fractyl Health? | Fractyl Health's last 12 months EBITDA is -$79.6M. |
| What is Fractyl Health's EBITDA margin? | Fractyl Health's last 12 months EBITDA margin is -146004%. |
| What is the current EV/EBITDA multiple of Fractyl Health? | Current EBITDA multiple of Fractyl Health is -1.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
